Open AccessLiver Targeting of Daclatasvir via Tailoring Sterically Stabilized Bilosomes: Fabrication, Comparative In Vitro/In Vivo Appraisal and Biodistribution Studies
Author(s) -
Mohamed A. El-Nabarawi,
Mohamed M. Nafady,
Shahira F. El-Menshawe,
Marwa Elkarmalawy,
Mahmoud H. Teaima
Publication year - 2021
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s319255
Subject(s) - polyethylene glycol , in vivo , peg ratio , biodistribution , materials science , hepatocyte , chemistry , biomedical engineering , in vitro , medicine , biochemistry , biology , microbiology and biotechnology , finance , economics
Hepatitis C virus (HCV) is a significant public health concern that threatens millions of individuals worldwide. Daclatasvir (DAC) is a promising direct-acting antiviral approved for treating HCV infection around the world. The goal of this study was to encapsulate DAC into novel polyethylene glycol (PEG) decorated bilosomes (PEG-BILS) to achieve enhanced drug delivery to the liver.